Patents by Inventor Corey REEVES
Corey REEVES has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20260015348Abstract: The present application provides compounds that may be used as a glucagon-like peptide-1 receptors (GLP-1R) agonist, or pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions containing such compounds, or pharmaceutically acceptable salts thereof. Methods of preparing these compounds and compositions, and methods of using these compounds and compositions to treat or prevent a disease or a condition mediated by GLP-1R, are also provided.Type: ApplicationFiled: June 18, 2025Publication date: January 15, 2026Inventors: Corey REEVES, Christopher T. JONES, Kevin QUINN, Gary W. LUEHR
-
Patent number: 12522596Abstract: The present application provides compounds that may be used as a glucagon-like peptide-1 receptors (GLP-1R) agonist, or pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions containing such compounds, or pharmaceutically acceptable salts thereof. Methods of preparing these compounds and compositions, and methods of using these compounds and compositions to treat or prevent a disease or a condition mediated by GLP-1R, are also provided.Type: GrantFiled: January 13, 2025Date of Patent: January 13, 2026Assignee: Terns Pharmaceuticals, Inc.Inventors: Corey Reeves, F. Anthony Romero, Christopher T. Jones, Martijn Fenaux
-
Patent number: 12486261Abstract: The present application provides compounds that may be used as a glucagon-like peptide-1 receptors (GLP-1R) agonist, or pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions containing such compounds, or pharmaceutically acceptable salts thereof. Methods of preparing these compounds and compositions, and methods of using these compounds and compositions to treat or prevent a disease or a condition mediated by GLP-1R, are also provided.Type: GrantFiled: May 13, 2024Date of Patent: December 2, 2025Assignee: Terns Pharmaceuticals, Inc.Inventors: Corey Reeves, F. Anthony Romero, Christopher T. Jones, Martijn Fenaux, Gary W. Luehr
-
Patent number: 12473289Abstract: The present disclosure provides compounds useful for the inhibition of Delta-5 Desaturase (“D5D”). The compounds have a general Formula 1: wherein the variables of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a metabolic or cardiovascular disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.Type: GrantFiled: November 24, 2020Date of Patent: November 18, 2025Assignee: AMGEN INC.Inventors: Jennifer R. Allen, Albert Amegadzie, Matthew P. Bourbeau, Ning Chen, Clifford Goodman, Giulia Lattanzi, Iain Lingard, Qingyian Liu, Jonathan D. Low, Vu Van Ma, Ana E. Minatti, Alfonso Pozzan, Corey Reeves, Aaron C. Siegmund, Sabrina Tassini, Federica Tonelli, Mary Walton Cabrera
-
Publication number: 20250282772Abstract: The present application provides compounds that may be used as a glucagon-like peptide-1 receptors (GLP-1R) agonist, or pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions containing such compounds, or pharmaceutically acceptable salts thereof. Methods of preparing these compounds and compositions, and methods of using these compounds and compositions to treat or prevent a disease or a condition mediated by GLP-1R, are also provided.Type: ApplicationFiled: November 22, 2024Publication date: September 11, 2025Inventors: Corey REEVES, F. Anthony ROMERO, Christopher T. JONES, Martijn FENAUX
-
Patent number: 12410163Abstract: The present application provides compounds that may be used as a glucagon-like peptide-1 receptors (GLP-1R) agonist, or pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions containing such compounds, or pharmaceutically acceptable salts thereof. Methods of preparing these compounds and compositions, and methods of using these compounds and compositions to treat or prevent a disease or a condition mediated by GLP-1R, are also provided.Type: GrantFiled: February 23, 2023Date of Patent: September 9, 2025Inventors: Corey Reeves, Christopher T. Jones, Kevin Quinn, Gary W. Luehr
-
Patent number: 12378236Abstract: The present application provides compounds that may be used as a glucagon-like peptide-1 receptors (GLP-1R) agonist, or pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions containing such compounds, or pharmaceutically acceptable salts thereof. Methods of preparing these compounds and compositions, and methods of using these compounds and compositions to treat or prevent a disease or a condition mediated by GLP-1R, are also provided.Type: GrantFiled: January 13, 2025Date of Patent: August 5, 2025Assignee: Terns Pharmaceuticals, Inc.Inventors: Corey Reeves, F. Anthony Romero, Christopher T. Jones, Martijn Fenaux
-
Patent number: 12378238Abstract: The present application provides compounds that may be used as a glucagon-like peptide-1 receptors (GLP-1R) agonist, or pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions containing such compounds, or pharmaceutically acceptable salts thereof. Methods of preparing these compounds and compositions, and methods of using these compounds and compositions to treat or prevent a disease or a condition mediated by GLP-1R, are also provided.Type: GrantFiled: January 13, 2025Date of Patent: August 5, 2025Assignee: Terns Pharmaceuticals, Inc.Inventors: Corey Reeves, F. Anthony Romero, Christopher T. Jones, Martijn Fenaux
-
Patent number: 12378237Abstract: The present application provides compounds that may be used as a glucagon-like peptide-1 receptors (GLP-1R) agonist, or pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions containing such compounds, or pharmaceutically acceptable salts thereof. Methods of preparing these compounds and compositions, and methods of using these compounds and compositions to treat or prevent a disease or a condition mediated by GLP-1R, are also provided.Type: GrantFiled: January 13, 2025Date of Patent: August 5, 2025Assignee: Terns Pharmaceuticals, Inc.Inventors: Corey Reeves, F. Anthony Romero, Christopher T. Jones, Martijn Fenaux
-
Patent number: 12378239Abstract: The present application provides compounds that may be used as a glucagon-like peptide-1 receptors (GLP-1R) agonist, or pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions containing such compounds, or pharmaceutically acceptable salts thereof. Methods of preparing these compounds and compositions, and methods of using these compounds and compositions to treat or prevent a disease or a condition mediated by GLP-1R, are also provided.Type: GrantFiled: January 13, 2025Date of Patent: August 5, 2025Assignee: Terns Pharmaceuticals, Inc.Inventors: Corey Reeves, F. Anthony Romero, Christopher T. Jones, Martijn Fenaux
-
Publication number: 20250145613Abstract: The present application provides compounds that may be used as a glucagon-like peptide-1 receptors (GLP-1R) agonist, or pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions containing such compounds, or pharmaceutically acceptable salts thereof. Methods of preparing these compounds and compositions, and methods of using these compounds and compositions to treat or prevent a disease or a condition mediated by GLP-1R, are also provided.Type: ApplicationFiled: January 13, 2025Publication date: May 8, 2025Inventors: Corey REEVES, F. Anthony ROMERO, Christopher T. JONES, Martijn FENAUX
-
Publication number: 20250145616Abstract: The present application provides compounds that may be used as a glucagon-like peptide-1 receptors (GLP-1R) agonist, or pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions containing such compounds, or pharmaceutically acceptable salts thereof. Methods of preparing these compounds and compositions, and methods of using these compounds and compositions to treat or prevent a disease or a condition mediated by GLP-1R, are also provided.Type: ApplicationFiled: January 13, 2025Publication date: May 8, 2025Inventors: Corey REEVES, F. Anthony ROMERO, Christopher T. JONES, Martijn FENAUX
-
Publication number: 20250145614Abstract: The present application provides compounds that may be used as a glucagon-like peptide-1 receptors (GLP-1R) agonist, or pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions containing such compounds, or pharmaceutically acceptable salts thereof. Methods of preparing these compounds and compositions, and methods of using these compounds and compositions to treat or prevent a disease or a condition mediated by GLP-1R, are also provided.Type: ApplicationFiled: January 13, 2025Publication date: May 8, 2025Inventors: Corey REEVES, F. Anthony ROMERO, Christopher T. JONES, Martijn FENAUX
-
Publication number: 20250145612Abstract: The present application provides compounds that may be used as a glucagon-like peptide-1 receptors (GLP-1R) agonist, or pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions containing such compounds, or pharmaceutically acceptable salts thereof. Methods of preparing these compounds and compositions, and methods of using these compounds and compositions to treat or prevent a disease or a condition mediated by GLP-1R, are also provided.Type: ApplicationFiled: January 13, 2025Publication date: May 8, 2025Inventors: Corey REEVES, F. Anthony ROMERO, Christopher T. JONES, Martijn FENAUX
-
Publication number: 20250145615Abstract: The present application provides compounds that may be used as a glucagon-like peptide-1 receptors (GLP-1R) agonist, or pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions containing such compounds, or pharmaceutically acceptable salts thereof. Methods of preparing these compounds and compositions, and methods of using these compounds and compositions to treat or prevent a disease or a condition mediated by GLP-1R, are also provided.Type: ApplicationFiled: January 13, 2025Publication date: May 8, 2025Inventors: Corey REEVES, F. Anthony ROMERO, Christopher T. JONES, Martijn FENAUX
-
Publication number: 20240391910Abstract: The present application provides compounds that may be used as a glucagon-like peptide-1 receptors (GLP-1R) agonist, or pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions containing such compounds, or pharmaceutically acceptable salts thereof. Methods of preparing these compounds and compositions, and methods of using these compounds and compositions to treat or prevent a disease or a condition mediated by GLP-1R, are also provided.Type: ApplicationFiled: May 13, 2024Publication date: November 28, 2024Inventors: Corey REEVES, F. Anthony ROMERO, Christopher T. JONES, Martijn FENAUX, Gary W. LUEHR
-
Patent number: 12024507Abstract: The present application provides compounds that may be used as a glucagon-like peptide-1 receptors (GLP-1R) agonist, or pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions containing such compounds, or pharmaceutically acceptable salts thereof. Methods of preparing these compounds and compositions, and methods of using these compounds and compositions to treat or prevent a disease or a condition mediated by GLP-1R, are also provided.Type: GrantFiled: October 25, 2022Date of Patent: July 2, 2024Assignee: Terns Pharmaceuticals, Inc.Inventors: Corey Reeves, F. Anthony Romero, Christopher T. Jones, Martijn Fenaux, Gary W. Luehr
-
Publication number: 20240059682Abstract: Provided herein are compounds, preferably thyroid hormone receptor beta (THR beta) agonist compounds, compositions thereof, and methods of their preparation, and methods of agonizing THR beta and methods for treating disorders ameliorated by activation of THR beta.Type: ApplicationFiled: March 2, 2022Publication date: February 22, 2024Inventors: Thorsten A. KIRSCHBERG, Corey REEVES, Kevin KLUCHER, Martijn FENAUX, Yingzi XU, F. Anthony ROMERO, Randall HALCOMB
-
Publication number: 20230322744Abstract: The present application provides compounds that may be used as a glucagon-like peptide-1 receptors (GLP-1R) agonist, or stereoisomers, tautomers, or pharmaceutically acceptable salts of any of the foregoing. Also provided are pharmaceutical compositions containing such compounds, or stereoisomers, tautomers, or pharmaceutically acceptable salts of any of the foregoing. Methods of prepare these compounds and compositions and method of using them to treat or present a disease or a condition mediated by GLP-1R.Type: ApplicationFiled: August 20, 2021Publication date: October 12, 2023Inventors: F. Anthony ROMERO, Christopher T. JONES, Martijn FENAUX, Corey REEVES, Thorsten A. KIRSCHBERG, Yingzi XU
-
Publication number: 20230322758Abstract: The present application provides compounds that may be used as a glucagon-like peptide-1 receptors (GLP-1R) agonist, or pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions containing such compounds, or pharmaceutically acceptable salts thereof. Methods of preparing these compounds and compositions, and methods of using these compounds and compositions to treat or prevent a disease or a condition mediated by GLP-1R, are also provided.Type: ApplicationFiled: February 23, 2023Publication date: October 12, 2023Inventors: Corey REEVES, Christopher T. JONES, Kevin QUINN, Gary W. LUEHR
